Zaprinast, a type V phosphodiesterase inhibitor, dilates capacitance vessels in anaesthetised rats

European Journal of Pharmacology

Volumn 351, Issue 3, 1998, Pages 323-328

  Ng, Sylvia S W ^a   Pang, Catherine C Y ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

Arterial resistance; Capacitance vessel; Circulatory filling pressure, mean; Phosphodiesterase, cGMP selective; Venous resistance; Zaprinast

Indexed keywords

MECAMYLAMINE; NITROPRUSSIDE SODIUM; NORADRENALIN; ZAPRINAST;

ANIMAL EXPERIMENT; ARTERY RESISTANCE; ARTICLE; BLOOD PRESSURE; CAPACITANCE BLOOD VESSEL; CHRONOTROPISM; CONTROLLED STUDY; DOSE RESPONSE; HEART OUTPUT; HEART RATE; HEMODYNAMICS; INTRAVENOUS DRUG ADMINISTRATION; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; VASCULAR RESISTANCE;

3',5'-CYCLIC-GMP PHOSPHODIESTERASE; ANIMALS; BLOOD PRESSURE; GANGLIONIC BLOCKERS; MALE; MECAMYLAMINE; NITROPRUSSIDE; NOREPINEPHRINE; PHOSPHODIESTERASE INHIBITORS; PHOSPHORIC DIESTER HYDROLASES; PURINONES; RATS; RATS, SPRAGUE-DAWLEY; VASCULAR CAPACITANCE; VASCULAR RESISTANCE; VASOCONSTRICTOR AGENTS; VASODILATION; VASODILATOR AGENTS; VEINS;

EID: 0031829362     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0014-2999(98)00319-7     Document Type: Article

References (24)

1. Abdelrahman, A., Pang, C.C.Y., 1992. Calcitonin gene-related peptide is a venous dilator in conscious rats. Eur. J. Pharmacol. 217, 185-189.
2. Ahn, H.S., Crim, W., Romano, M., Sybertz, E., Pitts, B., 1989. Effects of selective inhibitors of cyclic nucleotide phosphodiesterases of rabbit aorta. Biochem. Pharmacol. 38, 3331-3339.
3. De Garavilla, L., Pagani, E.D., Buchholz, R.A., Dundore, R., Bode, D.C., Volberg, M.L., Jackson, K.N., Pratt, P., Silver, P.J., 1996. Zaprinast, but not dipyridamole, reverses hemodynamic tolerance to nitroglycerin in vivo. Eur. J. Pharmacol. 313, 89-96.
4. 2-adrenoceptor antagonists on venous tone in conscious rats. Eur. J. Pharmacol. 182, 283-290.
5. D'Oyley, H.M., Tabrizchi, R., Pang, C.C.Y., 1989. Effects of vasodilator drugs on venous tone in conscious rats. Eur. J. Pharmacol. 162, 337-344.
6. Dundore, R.L., Habeeb, P.G., Pratt, P.F., Becker, L.T., Clas, D.M., Buchholz, R.A., 1992. Differential hemodynamic responses to selective inhibitors of cyclic nucleotide phosphodiesterases in conscious rats. J. Cardiovasc. Pharmacol. 19, 937-944.
7. Guyton, A.C., Jones, C.E., Coleman, T.G., 1973. Circulatory Physiology: Cardiac Output and its Regulation. Saunders, Philadelphia.
8. Ignarro, L.J., Byrns, R.E., Wood, K.S., 1987. Endothelium-dependent modulation of cGMP levels in intrinsic smooth muscle tone in isolated bovine intrapulmonary artery and vein. Circ. Res. 60, 82-92.
9. Lugnier, C., Schoeffter, P., Le Bee, A., Strouthou, E., Stoclet, J.C., 1986. Selective inhibition of cyclic nucleotide phosphodiesterases of human, bovine and rat aorta. Biochem. Pharmacol. 35, 1751-1753.
10. Martin, W., Furchgott, R.F., Villani, G.M., Jothianandan, D., 1986. Phosphodiesterase inhibitors induce endothelium-dependent relaxation of rat and rabbit aorta by potentiating the effects of spontaneously released endothelium-derived relaxing factor. J. Pharmocol. Exp. Ther. 237, 539-547.
11. McMahon, E.G., Palomo, M.A., Metha, P., Olins, G.M., 1989. Depressor and natriuretic effects of MandB 22,948, a guanosine cyclic 3′,5′-monophosphate-selective phosphodiesterase inhibitor. J. Pharmacol. Exp. Ther. 251, 1000-1005.
12. Merkel, L.A., Rivera, L.M., Perrone, M.H., Lappe, R.W., 1992. In vitro and in vivo interactions of nitrovasodilators and zaprinast, a cGMP-selective phosphodiesterase inhibitor. Eur. J. Pharmcaol. 216, 29-35.
13. Pagani, E.D., Vanller, G.S., O'Connor, B., Silver, P.J., 1993. Reversal of nitroglycerin tolerance in vitro by the cGMP-phosphodiesterase inhibitor zaprinast. Eur. J. Pharmacol. 243, 141-147.
14. Pang, C.C.Y., 1994. The Effects of Drugs in the Venous System. Medical Intelligence Unit, R.G. Landers, Austin, TX, pp. 1-139.
15. Polson, J.B., Strada, S.J., 1996. Cyclic nucleotide phosphodiesterase and vascular smooth muscle. Annu. Rev. Pharmacol. Toxicol. 36, 403-427.
16. Rothe, C.F., 1993. Mean circulatory filling pressure: its meaning and measurements. J. Appl. Physiol. 74, 499-509.
17. Szilvassy, Z., Jakab, I., Ferdinandy, P., Koltai, A., Lonovics, J., Tarrade, T., Braquet, P.G., 1993. Zaprinast, cicletanine, and verapamil attenuate overdrive pacing-induced myocardial ischemia in conscious rabbits. Life Sci. 53, 13-18.
18. Tabrizchi, R., Pang, C.C.Y., 1992. Effects of drugs on body venous tone, as reflected by mean circulatory filling pressure. Cardiovasc. Res. 26, 443-448.
19. Trapani, A.J., Smits, G.J., McGraw, D.E., McMahon, E.G., Blaine, E.H., 1991. Hemodynamic basis for the depressor activity of zaprinast, a selective cyclic GMP phosphodiesterase inhibitor. J. Pharmacol. Exp. Ther. 258, 269-274.
20. Villanueva, M.M., Nunes, J.P., Soares-Da-Silva, P., 1991. Relaxant effects of α-human atrial natriuretic peptide on venous smooth muscle. J. Auton. Pharmacol. 11, 139-145.
21. Waite, R.P., Pang, C.C.Y., Walker, M.J.A., 1988. Effects of calcium antagonists on mean circulatory filling pressure in the conscious rats. J. Cardiovasc. Pharmacol. 12, 499-504.
22. G-nitro-L-arginine on autonomie nerve activity. Br. J. Pharmacol. 103, 2004-2008.
23. G-nitro-L-arginine methyl ester (L-NAME) of resistance to venous return in rats. Br. J. Pharmacol. 114, 1454-1458.
24. Weishaar, R.E., Kobylarz-Singer, D.C., Keiser, J., Haleen, S.J., Major, T.C., Rapundalo, S., 1990. Subclasses of cyclic GMP-specific phosphodiesterase and their role in regulating the effects of natriuretic factor. Hypertension 15, 528-540.